NEW YORK, March 22, 2017 /PRNewswire/ -- The multidistrict litigation established in the U.S. District Court, Eastern District of Louisiana, for all federally-filed Taxotere lawsuits involving permanent alopecia convened two conferences this month. According court records, a Status Conference was convened on March 16th specifically to address issues relating to Electronically Stored Information (ESI). The proceeding's regular monthly Status Conference was held on March 17th, during which time a number of matters, including the progress of discovery and motions practice, were addressed. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm is monitoring this proceeding closely, as we have been retained by a number of individuals seeking to file Taxotere hair loss claims. In addition, we continue to receive inquiries from other potential plaintiffs on a fairly regular basis," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss allegedly associated with Taxotere cancer treatment.
Taxotere and Permanent Alopecia
Court documents indicate that nearly 800 Taxotere lawsuits are now pending in the Eastern District of Louisiana, all of which were filed on behalf of cancer patients who experienced the permanent loss of hair following treatment with the chemotherapy medication. While alopecia is not at all unusual in patients undergoing chemotherapy, plaintiffs claim that hair loss associated with Taxotere is more likely to be permanent compared to equally effective, alternative drugs. They further claim that by the late 1990s, Sanofi-Aventis and other defendants had knowledge of research indicating that 9.2 percent of Taxotere patients experienced persistent alopecia for up to 10 years or longer. In 2006, an oncologist in Denver had also reported that a higher percentage of his Taxotere patients suffered from permanent hair loss for years after their treatment had ceased
Taxotere was approved by the U.S. Food & Drug Administration in 1996 to treat breast cancer, and has since been cleared to treat a number of other malignancies. However, it was only in December 2015 that any information regarding reports of permanent alopecia was added to the drug's U.S. label. Plaintiffs question why Sanofi has long provided information regarding the potential for permanent hair loss to individual patients and regulatory agencies overseas, while the Taxotere label for the U.S. market only included generic, vague, and insufficient warning that "hair generally grows back".
Taxotere cancer patients who experienced persistent, permanent alopecia following chemotherapy with this medication may be entitled to compensation. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP